U.S. Pharmaceuticals & Biotech Nano Cap Stocks

Cumberland Pharmaceuticals

Market Cap: US$45.9m

A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.

MariMed

Market Cap: US$45.1m

Engages in cultivation, production, and selling of branded cannabis products in the United States and internationally.

Clene

Market Cap: US$42.4m

A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

Bioqual

Market Cap: US$38.6m

Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.

NeuroSense Therapeutics

Market Cap: US$30.8m

A clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.

Enlivex Therapeutics

Market Cap: US$29.6m

Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Cingulate

Market Cap: US$21.9m

A biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.

Adaptimmune Therapeutics

Market Cap: US$18.6m

A commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

Neuphoria Therapeutics

Market Cap: US$14.6m

A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.

Pharma-Bio Serv

Market Cap: US$13.8m

Operates as a regulatory affairs, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.

TherapeuticsMD

Market Cap: US$13.2m

Operates as a pharmaceutical royalty company in the United States.

Brainstorm Cell Therapeutics

Market Cap: US$6.4m

A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.

Mainz Biomed

Market Cap: US$6.2m

Develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe.

CordovaCann

Market Cap: US$5.5m

Engages in identifying, funding, developing, and managing operations in the cannabis value chain business.

China Pharma Holdings

Market Cap: US$4.8m

Develops, manufactures, and markets pharmaceutical products for human use in the People’s Republic of China.

NovaBay Pharmaceuticals

Market Cap: US$3.6m

Does not have significant operations.

Bio Essence

Market Cap: US$3.6m

Engages in the manufacturing and distributing health supplement products.

Can B

Market Cap: US$1.7m

Engages in the protection and commercialization of cannabis patents.

Target Group

Market Cap: US$833.0k

Target Group Inc. cultivates, processes, and distributes curated cannabis products for the medical and adult-use recreational cannabis market in Canada and the United States.

Maple Leaf Green World

Market Cap: US$93.1k

Does not have significant operations.

Sunset Island Group

Market Cap: US$34.4k

Through its subsidiary, VBF Brands, engages in the cultivation of medical cannabis in California, the United States.

Cannonau

Market Cap: US$24.2k

Engages in the provision of cannabidiol based products.

Biostax

Market Cap: US$17.3k

Operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products.